Aktienanalyse zu Tenax Therapeutics Inc (TENX)TENXTenax Therapeutics Inc

Tenax Therapeutics, Inc. is a Phase 3 development-stage pharmaceutical company. The Company is focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The Company's products include TNX-201 (oral enteric-coated imatinib) and TNX-103 (oral levosimendan). The Company is developing dosing and a formulation of imatinib mesylate, a kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The Company’s other programs include TNX-101 and TNX-102. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The Company has completed the Phase II trial of levosimendan in patients with PH and heart failure with preserved ejection fraction (HFpEF). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Given the current price of $1.80 and the significant downgrades from analysts, including a target reduction to $4 from $40, this stock is not a good buy right now. The company is also facing a class action lawsuit, which adds to the risk. The forward P/E ratio is extremely low at 0.299, indicating potential undervaluation, but the overall sentiment and financial performance suggest caution. The main risk is the ongoing class action lawsuit that could impact investor sentiment and stock performance.

1 analysts cover TENX: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 25.00.